Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes

• Status: Completed
• Trial end date: 2007-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The study was performed to assess: 1) clinical activity of Imatinib in patients with HES, CEL and CIH; 2) correlation between Imatinib activity and specific disease subtype; 3) long-term outcome of HES, CEL and CIH patients treated with Imatinib; 4) safety and tolerability of Imatinib administration.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Northern Italy Leukemia Group
• Treatments: Imatinib Mesylate

Criteria

Inclusion Criteria:

• patients with a diagnosis of HES, CEL and CIH, who are either previously untreated or have been treated with corticosteroids, cytotoxic drugs, and IFN.

• age > 15 years.

• signature of a written informed consent(by parents/tutors for patients aged < 18 years).

Exclusion Criteria:

• patients with a diagnosis of secondary hypereosinophilia

• age < 15 years